Although cardiac troponin is associated with outcomes in atrial fibrillation (AF), the complementary prognostic information provided by cardiac troponin I (cTnI) and cTnT is unknown. This study investigated the distribution, determinants, and prognostic value of cTnI and cTnT concentrations in patients with AF.
for a history of congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65-74 years, and female sex and 2 points for age Ն75 years and prior stroke/transient ischemic attack) (6 -8 ) . Cardiac troponin I (cTnI) and cTnT, principally on the basis of the results of conventional assays, have been regarded to be comparable in terms of detection of myocardial damage (9 ) . However, recent studies of high-sensitivity troponin assays have found differences between cTnI and cTnT with regard to diagnostic performance and prognostication (10, 11 ) . At present, it is unknown if the distributions of cTnI and cTnT concentrations differ and if these 2 troponin biomarkers provide similar or complementary prognostic information in patients with AF.
Within the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial of patients with AF and a raised risk for stroke, we obtained plasma samples for central biomarker analyses from 14 897 of 18 201 patients at entry to the trial (12, 13 ) . In this biomarker substudy, we assessed the distribution and compared and combined the prognostic value of cTnI and cTnT measured with highsensitivity methods in patients with AF.
Methods

THE ARISTOTLE TRIAL
The details of the ARISTOTLE trial have been published previously (13 ) . Briefly, ARISTOTLE was a doubleblind, double-dummy, randomized clinical trial that enrolled 18 201 patients with AF and at least 1 CHADS 2 risk factor (congestive heart failure, hypertension, age Ն75 years, diabetes mellitus, prior stroke/transient ischemic attack) for stroke or systemic embolism (6 ) . Between December 2006 and April 2010, patients were recruited from 1034 centers in 39 countries and randomized to warfarin (n ϭ 9081) or apixaban (n ϭ 9120). The primary endpoint was stroke or systemic embolism. Bleeding was classified according to International Society on Thrombosis and Hemostasis (ISTH) criteria. The median length of follow-up was 1.9 years (interquartile range 1.5-2.4 years) for the participants with troponin measurements available.
END POINTS AND CLINICAL RISK CLASSIFICATION
The end points in this study included stroke or systemic embolism; ischemic stroke or systemic embolism, hemorrhagic stroke, myocardial infarction; all-cause mortality; cardiac death (excluding bleeding and other noncardiac causes); and ISTH major bleeding. Composites included stroke or systemic embolism, total death or cardiac death, and myocardial infarction. A blinded clinical events committee using prespecified criteria adjudicated all end points (13 ) .
BIOCHEMICAL METHODS
At randomization, all patients provided blood samples, which were collected into Vacutainer tubes containing EDTA and centrifuged immediately. Plasma was frozen in aliquots and stored at Ϫ70°C until analyzed centrally at the Uppsala Clinical Research Center (UCR), an academic platform for analyses of biomarkers at the Uppsala University Hospital, Uppsala, Sweden. Troponin is stable in long-term frozen samples, and the average storage time was 4.1 years (14, 15 ) . The cTnI concentrations were measured on the Architect i1000SR (Abbott Diagnostics) according to the instructions of the manufacturer. With this assay as determined in the UCR laboratory, the dynamic range is 0.7-50 000 ng/L, the limit of detection is 1.3 ng/L, and the limit of quantification is 3.3 ng/L on the basis of the 10% CV, with a local CV of 7% at 21 ng/L. The 99th percentile upper reference limit for healthy individuals is 23 ng/L in lithium heparin (16 ) . The cTnT concentrations were measured on the Cobas ® Analytics e601 Immunoanalyzer (Roche Diagnostics) according to the instructions of the manufacturer. According to the manufacturer, the measuring range is 3-10 000 ng/L, limit of detection 5 ng/L, and limit of quantification 13 ng/L on the basis of the 10% CV, with a local CV of 3% at 27 ng/L in the UCR laboratory. The 99th percentile upper reference limit for healthy individuals is 14 ng/L (17 ) .
Cystatin C was analyzed with the Architect System ci8200 (Abbott Laboratories) with the particle enhanced turbidimetric immunoassay from Gentian. The total analytical imprecision of the method is 1.09% at 0.85 mg/L and 1.03% at 3.06 mg/L (18 ) . N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations were measured on the Cobas Analytics e601 Immunoanalyzer according to the instructions of the manufacturer. The lower limit of detection for NT-proBNP with this assay is 5 ng/L. The analytical range extends from 20 to 35000 ng/L according to the manufacturer. The lowest concentration with a CV Ͻ10% is 30 ng/L, with a local CV of 3% at 125 ng/L in the UCR laboratory (19 ) .
STATISTICAL ANALYSES
Statistical analyses included the data of 14 806 patients who provided blood samples for the biomarker study at randomization and also had available results of the evaluated biomarkers. Four groups were defined by median concentrations of troponin: group 1, both troponins below median; group 2, low cTnI and high cTnT; group 3, high cTnI and low cTnT; and group 4, both troponins above median. Demographics and other baseline characteristics were summarized by use of frequencies for categorical variables and median and 25th and 75th percentiles for continuous variables. For tests of differences among groups, we used the 2 test for categorical variables and Kruskal-Wallis test for continuous variables.
We evaluated the correlation between cTnI and cTnT concentrations with the Spearman rank correlation coefficient.
We used multivariable analysis of variance with natural logarithms of cTnI or cTnT as response variable and categorized baseline characteristics as explanatory variables to investigate the independent effect of each variable. Geometric means, calculated by antilogs of the model-adjusted means, were compared.
Efficacy analyses included all randomized patients and all events from randomization until the efficacy cutoff date (predefined as January 30, 2011). Bleeding analyses were "on treatment," including all randomized patients who received at least 1 dose of study drug and all events from receipt of the study drug until 2 days after the last dose of the study drug.
In previous studies, no significant interactions between study treatment and either cTnI or cTnT concentrations have been found for any of the outcomes (7, 8 ) . The randomized treatment groups were therefore combined and adjusted for when evaluating the association between troponin groups and the above outcomes in the multivariable analyses. The outcomes in relation to cTnI and cTnT groups were evaluated in both a Cox proportional hazards model adjusted for study treatment and a multivariable model. The multivariable analyses included established risk factors (age, sex, body mass index, smoking status, systolic blood pressure, heart rate, atrial fibrillation type, diabetes, heart failure, previous stroke/ systemic embolism/transient ischemic attack, hypertension, previous myocardial infarction, previous peripheral artery disease/coronary artery bypass graft/percutaneous coronary intervention, treatment at randomization with aspirin, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers, and amiodarone for the major bleeding end point; history of anemia and history of spontaneous or clinical relevant bleeding were also included), randomized treatment, region, use of warfarin within 7 days before randomization, use of statin medication within 30 days before randomization, and biomarkers [cystatin C (marker of renal function) and NTproBNP]. The hazard ratios (HRs) and 95% CIs, by use of the group with both troponins below median as reference, were reported. The increased discriminative value of the troponins was investigated by estimating the c-statistics generalized for survival data for models before and after the addition of 1 troponin method (quartile groups) to the other, and also the continuous (category free) net reclassification improvement (NRI) for survival data as described by Harrell et al. (20 ) and Pencina et al. (21 ) . We performed likelihood ratio tests to evaluate whether the global model fit improved after addition of the other troponin method.
Kaplan-Meier estimates of the cumulative hazard were calculated and plotted. All presented event rates were reported per 100 patient-years of follow up. All statistical tests were 2-tailed and performed at the 0.05 significance level. There were no adjustments for multiple comparisons. The statistics section at UCR conducted the statistical analyses. All statistical analyses were performed with SAS software version 9.3 (SAS Institute).
Results
DISTRIBUTION LEVELS OF CARDIAC TROPONINS WITH HIGH-SENSITIVITY ASSAYS
Both troponin subtypes were measurable in most participants. cTnI was measurable in 98.5% and Ն99th percentile value in 9.2% of the participants, with a median concentration of 5.4 ng/L (25th and 75th percentiles of 3.3 and 10.1 ng/L, respectively). cTnT was measurable in 93.5% and Ն99th percentile value in 34.4% of the participants, with a median concentration of 10.9 ng/L (25th and 75th percentiles of 7.5 and 16.7 ng/L, respectively). Distribution of each troponin subtype is illustrated in Fig. 1 . The correlation between cTnI and cTnT concentrations was moderate, with a Spearman coefficient of 0.70 (P Ͻ 0.0001) (see Supplemental Fig. A , which accompanies the online version of this article at http://www.clinchem.org/content/vol61/issue2). A total of 5819 participants (39.3%) had both cTnI and cTnT below median, 1651 (11.2%) cTnI below and cTnT above median, 1660 (11.2%) cTnI above and cTnT below median, and 5676 (38.3%) both cTnI and cTnT above median.
BASELINE CHARACTERISTICS AND DETERMINANTS
In Table 1 baseline demographics are displayed stratified by medians of cTnI and cTnT concentrations. Patients with both cTnI and cTnT above median were generally older and had more comorbidity compared with the group with both troponins below median. Patients with only 1 troponin subtype (I or T) above median displayed noticeable differences in relation to clinical variables. Patients with only cTnT above median, compared with the group with only cTnI above median, were older and more often male and had more frequent diabetes mellitus and lower renal function. In comparison, patients with only cTnI above median had a higher occurrence of heart failure. Correspondingly, in the multivariable analysis, age, male sex and diabetes mellitus were the main determinants of cTnT concentrations, whereas congestive heart failure, vascular disease, and persistent/permanent AF were the determinants of cTnI concentrations (Table  2) . However, in the multivariable analysis, renal impairment was the most important determinant of increased troponin concentrations, with a similar influence on both markers (P Ͻ 0.0001 for both) ( Table 2) .
COMBINED USE OF HIGH-SENSITIVITY cTnI AND cTnT MEASUREMENTS IN RELATION TO STROKE AND CARDIOVASCULAR OUTCOMES
During follow-up over a median of 1.9 years (annual rates), a total of 395 (1.40%) patients experienced stroke or systemic embolism, 537 (1.88%) died from a cardiac cause, 149 (0.52%) had myocardial infarctions, and 670 (2.61%) had major bleeding events in this substudy cohort.
Troponin concentrations above median were strongly and significantly associated with a higher rate of all outcome events, even after adjustment for baseline characteristics and indicators of myocardial and renal dysfunction in the multivariable model (Table 3) . With regard to stroke or systemic embolism outcomes, patients with both troponins above median had a significantly higher risk than those with both cTnI and cTnT below median, with an adjusted HR of 1.72 (P ϭ 0.0014) (Table 3). Patients with isolated increases, where 1 but not both troponin subtypes were above median, had an intermediate risk, with HRs of 1.35 and 1.21, respectively, compared with the group with both troponins below median. Cardiac mortality rates increased with troponin concentrations, with an adjusted HR of 3.14 in the group with both cTnI and cTnT above median compared with the group having both troponins below median (Table  3) . Patients with an isolated increase of 1 but not both troponin subtypes also had a significantly higher risk, with HRs up to 1.97 compared with the group with both troponins below median. For myocardial infarction, despite the overall low event rates, there was a similar association of cTnI and cTnT concentrations with a significantly raised risk if either of the troponins was above median, and even more so if both troponins were above median, yielding an adjusted HR of 2.99 (1.78 -5.03) compared with the group with both troponins below median. Isolated increases of cTnI concentrations generally seemed to be associated with higher event rates compared with isolated increases in cTnT (Table 3 ). This pattern was most pronounced for cardiac death and myocardial infarction outcomes. Patients with isolated cTnI increases had approximately 66% higher annual rates of cardiac mortality compared with patients with isolated cTnT increases (1.59% vs 0.96%) (Table 3) , and 32% higher rates of myocardial infarctions (0.58% vs 0.44%) ( Table 3 ). Isolated increases of cTnT, on the other hand, displayed a stronger association with major bleeding events. The rates of the composite of the individual events as well as major bleeding events demonstrated correspondingly highly significant associations with increased troponin concentrations. As illustrated in the Kaplan-Meier plots (Fig. 2,  A and B) , the associations between troponin concentrations at baseline and the risk for subsequent events remained stable over time.
There was no significant interaction for any of the outcomes in relation to the randomized treatments with the combined troponin groups (data not shown). Thus, assignment to apixaban was associated with reductions in stroke or systemic embolism, cardiac mortality, myocardial infarction, and bleeding consistent with the overall trial irrespective of troponin subgroups (all interaction P values Ͼ0.46).
INCREMENTAL VALUE OF ADDING MEASUREMENT OF 1 CARDIAC TROPONIN SUBTYPE TO THE OTHER
For stroke or systemic embolic events, the addition of cTnI to cTnT (or vice versa) on top of the established risk factors including biomarkers (cystatin C and NTproBNP) did not improve risk stratification (P Ͼ 0.11). However, each troponin subtype was independently associated with cardiac death as well as myocardial infarction outcomes (P Յ 0.001 and P Ͻ 0.05, respectively, for cTnI and cTnT). The discriminative value of each tro- ponin subtype was evaluated by c-statistics in similar modeling and by assessing the continuous NRI (Table 4) . There was no added benefit of adding 1 troponin subtype to the other, on top of established risk factors and other biomarkers, for prediction of stroke outcomes. For cardiac death and myocardial infarction outcomes, the c-index improved slightly by addition of cTnI, as well as by addition of cTnT (Table 4) . For major bleeding outcomes, the addition of cTnT, but not cTnI, improved the predictive model. Both troponins positively reclassified patients according to NRI (Table 4) , mainly among events.
Discussion
The central findings from the present ARISTOTLE biomarker study were that, although cTnI and cTnT can be detected in almost all patients with AF and at least 1 clinical risk factor for stroke, the correlation between the troponins was modest. On the basis of median values as cutoffs, approximately 80% were similarly classified by both troponin methods, with no significant differences concerning prediction of stroke. Isolated increases in cTnI more consistently indicated the presence of cardiac disease such as heart failure, persistentpermanent AF, and vascular disease, factors that all contribute to a raised risk of stroke. Isolated increases in cTnT indicated the presence of other risk factors for stroke such as higher age and diabetes mellitus. cTnI was slightly more strongly associated with other cardiovascular events than cTnT. In the presence of clinical information, the use of either of these highsensitivity troponins offers similar prognostication, a Data ratio of geometric mean (95% CI). The variables with differences in geometric means of ≥20% for either cTnI or cTnT are displayed; all were significant with P values <0.0001 from multivariable ANOVA, with the natural logarithms of cTnT and cTnI, respectively, as outcome variable and baseline characteristics as independent variables. Also included in the model were smoking status, heart rate, previous stroke/systemic embolism/transient ischemic attack, hypertension, body mass index, baseline statin treatment, and baseline warfarin/vitamin K antagonist treatment. b Prior percutaneous coronary intervention/coronary artery bypass surgery/peripheral arterial disease. and the measurement of both provides no substantial additional information.
Cardiac troponins have in previous studies displayed independent and strong prognostic information in several cardiovascular diseases and recently in AF (5, 8, (22) (23) (24) (25) (26) . In earlier studies, cardiac troponin subunits I and T had been regarded to be comparable in terms of risk stratification. However, in recent studies that used highsensitivity troponin assays, interesting differences between cTnI and cTnT have been described. In patients with stable coronary artery disease enrolled in the Prevention of Events with Angiotensin-Converting Enzyme (PEACE) trial, cTnI measurements with high-sensitivity assays displayed independent prognostic information on top of established risk factors and biomarkers, including cTnT, for a composite end point consisting of cardiovascular death and heart failure outcomes (10 ) . In the present study, the complementary value of using combined a Model included the following risk factors: age, sex, body mass index, smoking status, systolic blood pressure, heart rate, atrial fibrillation type, diabetes, heart failure, previous stroke/systemic embolism/transient ischemic attack, hypertension, previous myocardial infarction, prior percutaneous coronary intervention/coronary artery bypass surgery/peripheral arterial disease, treatment at randomization with aspirin, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, amiodarone, and biomarkers (cystatin C, NT-proBNP). measurements of both troponin subtypes in patients with AF was evaluated statistically for each of the outcomes: stroke, cardiac death, myocardial infarction, and major bleeding; these evaluations, however, did not translate to a substantial additional clinical improvement in prognostication over the use of clinical risk factors, NT-proBNP, cystatin C, and either cTnT or cTnI. A part of the increased risk found with combined troponin increases might be explained by the higher troponin concentrations observed with combined increases compared with the groups with isolated troponin increases. Clinical variables such as age, sex, and renal function have generally been associated with troponin concentrations (7, 8, (27) (28) (29) . In the present study, the measurement of both cTnI and cTnT with high-sensitivity assays in the same cohort of patients with blood samples collected at the same point in time permitted reliable analyses of the association of clinical variables to troponin concentrations and potential differences between the troponin subtypes. It was apparent that the correlation between cTnT and cTnI in this AF cohort was relatively moderate, a finding that has also been described in other populations (10, 15 ) . The median value for cTnT was close to the 99th percentile concentration, whereas the median concentration for cTnI was only one-fourth of the 99th percentile concentration. Both troponin subtypes shared similar determinants, but patients in the group with isolated cTnT increases were older and had a larger male proportion and poorer renal function than patients with isolated cTnI increases. By contrast, isolated cTnI increases were more common in AF patients with signs of more pronounced cardiac disease such as presence of heart failure, coronary artery disease, and, to a larger degree than cTnT, a higher AF burden (persistent and permanent vs paroxysmal). Both troponin subunits had in common that moderate to severe renal dysfunction was the single strongest clinical variable influencing their concentrations.
There are some structural differences between cTnI and cTnT that may contribute to these dissimilarities (14 ) . cTnT, for instance, is larger and has a higher molecular weight (37 kDa) than cTnI (24 kDa), which may contribute to the distribution pattern concerning isolated cTnT increases in patients with renal dysfunction. In addition cTnI, but not cTnT, has been associated with increased concentrations in proportion to the severity of myocardial ischemia (10, 30 ) . These differences, together with the relatively moderate correlation, suggest that the release and elimination mechanisms may not be completely the same for cTnI and cTnT and possibly reflect different degrees of influence by various pathophysiological pathways that could account for the differences displayed in the present study. It is important, however, to be aware of the possibility that the differences between cTnI and cTnT may be due to dissimilarities in the assay properties and not biological differences of the troponin molecules per se. Assay interferences, detectionand capture antibody epitope properties, autoantibodies, or posttranslational modifications such as proteolytic degradation and phosphorylation may influence the measurements to different extents (14, 31 ) . For instance, differences have previously been described between cTnI assays of different sensitivities (32, 33 ) . On the other hand, in the presence of background clinical informa- tion, the differences in the predictive values were marginal and measurement of either troponin therefore seems sufficient for prognostication of risk in AF. Our results were derived from a clinical trial population with AF and at least 1 risk factor for stroke and therefore may not apply to a general population. Parts of the observed differences between cTnI and cTnT may be due to analytical differences between the assays rather than biological differences, although both troponins were analyzed with high-sensitivity assays with high precision.
In conclusion, cTnI and cTnT are detectable in a vast majority of patients with AF, although their correlation is only moderate. Our findings show that the risk of stroke and cardiovascular events is highest in patients with increased concentrations of both troponins. However, when considered with information from other clinical risk factors, cTnI and cTnT provide similar prognostic information. 
